EGFR-TKIs such as gefitinib, erlotiniband afatinibare currently used in the clinical treatment of cancer [5, 6] and compared to standard chemotherapy treatments, first-line treatment with EGFR-TKIs induces favorable anti-tumor responses. This evidence concerns the gene EGFR and neoplasm.